To analyze factors associated with changes in prescription drug use and expenditures in the United States from 1999 to 2016, a period of rapid growth, deceleration, and resumed above‐average growth.
Data Sources/Study Setting
The Medical Expenditure Panel Survey (), containing household and pharmacy information on over five million prescription drug fills.
We use nonparametric decomposition to analyze drug use, average payment per fill, and per capita expenditure, tracking the contributions over time of socioeconomic characteristics, health status and treated conditions, insurance coverage, and market factors surrounding the patent cycle.
Data Collection/Extraction Methods
Medical Expenditure Panel Survey data were combined with information on drug approval dates and patent status.
Per capita utilization increased by nearly half during 1999‐2016, with changes in health status and treated conditions accounting for four‐fifths of the increase. In contrast, per capita expenditures more than doubled, with individual characteristics only explaining one‐third of the change. Other drivers of spending during this period include the changing pipeline of new drugs, drugs losing exclusivity, and changes in generic competition.
Long‐term trends in treated conditions were the fundamental drivers of medication use, whereas factors involving the patent cycle accelerated and decelerated spending growth relative to trends in use.
